OncoGenex Pharmaceuticals, Inc.
) recently announced the commencement of a phase II trial,
Spruce, on its oncology candidate OGX-427.
We note that OncoGenex is evaluating OGX-427 for the treatment
of previously untreated advanced non-squamous non-small cell lung
The investigator-sponsored, randomized, double-blind,
placebo-controlled phase II study, Spruce, will randomize 155
patients suffering from non-squamous NSCLC to receive carboplatin
and Alimta plus either OGX-427 or placebo.
The primary endpoint of the trial is progression-free survival
We note that apart from Spruce, OGX-427 will be evaluated
under another phase II trial for NSCLC - Cedar. The trials are
part of the ORCA (Ongoing Studies Evaluating Treatment Resistance
in CAncer) program, which is evaluating OGX-427 for the treatment
of advanced cancers.
In the Cedar study, patients will be randomized to receive
OGX-427 plus Gemzar and carboplatin or Gemzar and carboplatin
alone. This study, which is scheduled to commence later this
year, will be conducted in patients with previously untreated,
advanced, squamous cell lung cancer.
Apart from OGX-427, OncoGenex is developing custirsen in
Teva Pharmaceutical Industries Ltd.
Custirsen, a phase III candidate, is being developed for the
treatment of metastatic castrate-resistant prostate cancer in
men. Custirsen is also being evaluated for NSCLC.
The successful development and commercialization of both these
candidates will be a major positive for OncoGenex. OncoGenex
currently has no approved drug in its portfolio. We expect
investor focus to remain on both Spruce and Cedar along with
updates on custirsen.
OncoGenex currently carries a Zacks Rank #3 (Hold). Right now,
) look attractive, each with a Zacks Rank #2 (Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ONCOGENEX PHARM (OGXI): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.